Review
Oncology
Nicholas C. P. Cross, Thomas Ernst, Susan Branford, Jean-Michel Cayuela, Michael Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Katerina Machova Polakova, Jerald P. Radich, Ruediger Hehlmann, Andreas Hochhaus, Jane F. Apperley, Simona Soverini
Summary: The article discusses laboratory management methods for patients with CML, including accurate diagnosis, assessment of prognostic markers, sequential assessment of residual disease levels, and investigation of reasons for resistance, relapse, or progression. The recommendations focus on current best practices and highlight the strengths and pitfalls of commonly used laboratory tests.
Article
Oncology
Susana Elaine Alves da Rosa, Larissa Barbosa de Lima, Caroline Nunes Silveira, Luiz Gustavo Ferreira Cortes, Joao Bosco de Oliveira Filho, Rodrigo de Souza Reis, Murilo Castro Cervato, Pedro Henrique Sebe Rodrigues, Karla de Oliveira Pelegrino, Roberta Cardoso Petroni, Erica da Silva Araujo, Paulo Vidal Campregher
Summary: This study describes a real-world genomic profiling experience in AML and demonstrates the impact of the European Leukemia Net 2022 update on risk stratification in AML.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Hematology
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippe, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano
Summary: Experts from the MRD Working Party of the European LeukemiaNet evaluated the key factors for accurate MFC-MRD measurement in acute myeloid leukemia (AML) and provided recommendations to ensure quality and reproducibility of results. The recommendations were tested by comparing two 8-color MRD panels in multiple laboratories, confirming their feasibility.
Article
Hematology
Alex Bataller, Ana Garrido, Francesca Guijarro, Guadalupe Onate, Marina Diaz-Beya, Montserrat Arnan, Mar Tormo, Susana Vives, Maria Paz Queipo de Llano, Rosa Coll, David Gallardo, Ferran Vall-Llovera, Lourdes Escoda, Antonio Garcia-Guinon, Olga Salamero, Antonia Sampol, Brayan M. Merchan, Joan Bargay, Sandra Castano-Diez, Daniel Esteban, Aina Oliver-Caldes, Andrea Rivero, Pablo Mozas, Monica Lopez-Guerra, Marta Pratcorona, Lurdes Zamora, Dolors Costa, Maria Rozman, Josep F. Nomdedeu, Dolors Colomer, Salut Brunet, Jorge Sierra, Jordi Esteve
Summary: The 2017 European LeukemiaNet guidelines for acute myeloid leukemia have been validated in a large cohort of patients and identified a genetic subset with a very poor prognosis.
Article
Biophysics
Enrico Maffini, Myriam Labopin, Dietrich Wilhelm Beelen, Nicolaus Kroeger, Mutlu Arat, Keith M. O. Wilson, Jacques-Olivier Bay, Arnold Ganser, Hans Martin, Jakob Passweg, Panagiotis D. Kottaridis, Ibrahim Yakoub-Agha, Rocio Parody Porras, Eva Maria Wagner, Jordi Esteve, Francesco Lanza, Arnon Nagler, Mohamad Mohty
Summary: This study assessed the impact of MRD assessment on post-HCT outcomes among adult patients with sAML in first complete remission. The results showed that MRD status at the time of HCT did not have any effect on patient outcomes.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Jianming Shao, Shilpan Shah, Siddhartha Ganguly, Youli Zu, Chuan He, Zejuan Li
Summary: Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML), but current methods cannot detect MRD in many patients. We developed a highly sensitive 5-hydroxymethylcytosine (5hmC) signature in cell-free DNA that can detect MRD in AML patients with negative MRD by other methods. This novel method is significantly associated with relapse-free survival and may greatly impact AML patient management.
CLINICAL EPIGENETICS
(2023)
Article
Oncology
Krzysztof Mrozek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld
Summary: Recently, the European LeukemiaNet revised the genetic-risk classification of acute myeloid leukemia (AML), leading to changes in the percentage of patients in different risk groups. The new classification accurately reflected treatment outcomes in most patients, but there were discrepancies in certain age and ethnic groups. The prediction abilities of the new and old classifications were similar, and the significance of some newly added markers was confirmed and challenged.
Article
Cardiac & Cardiovascular Systems
Victor Aboyans, Rupert Bauersachs, Lucia Mazzolai, Marianne Brodmann, Jose F. Rodriguez Palomares, Sebastian Debus, Jean-Philippe Collet, Heinz Drexel, Christine Espinola-Klein, Basil S. Lewis, Marco Roffi, Dirk Sibbing, Henrik Sillesen, Eugenio Stabile, Oliver Schlager, Marco De Carlo
Summary: The collaborative document aims to update clinicians on optimal antithrombotic strategies for patients with aortic and/or peripheral arterial diseases. It highlights the importance of a regular reassessment of antithrombotic therapy based on individual patient's ischaemic and bleeding risks, as well as therapeutic paths.
EUROPEAN HEART JOURNAL
(2021)
Article
Biophysics
Arnon Nagler, Maud Ngoya, Galimard Jacques-Emmanuel, Myriam Labopin, Nicolaus Kroeger, Gerard Socie, Tobias Gedde-Dahl, Victoria Potter, Thomas Schroeder, Uwe Platzbecker, Arnold Ganser, Didier Blaise, Urpu Salmenniemi, Johan Maertens, Charles Craddock, Helene Labussiere-Wallet, Ibrahim Yakoub-Agha, Bipin Savani, Mohamad Mohty
Summary: In transplantation for sAML, the non-relapse mortality has significantly reduced and the modified GVHD-free, relapse-free survival has improved in the past 2 decades.
BONE MARROW TRANSPLANTATION
(2022)
Review
Oncology
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, Ryosuke Tateishi, Kazuya Kariyama, Shuichiro Shiina, Hidenori Toyoda, Yasuharu Imai, Atsushi Hiraoka, Masafumi Ikeda, Namiki Izumi, Michihisa Moriguchi, Sadahisa Ogasawara, Yasunori Minami, Kazuomi Ueshima, Takamichi Murakami, Shiro Miyayama, Osamu Nakashima, Hirohisa Yano, Michiie Sakamoto, Etsuro Hatano, Mitsuo Shimada, Norihiro Kokudo, Satoshi Mochida, Tetsuo Takehara
Summary: The Clinical Practice Manual for Hepatocellular Carcinoma is based on evidence and expert consensus, focusing on pathology, diagnosis, and treatment. Different from the JSH Clinical Practice Guidelines, this manual emphasizes practicality and is written by a panel of experts from the JSH.
Article
Hematology
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Herve Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gokbuget, Jason Gotlib, Eva Hellstrom-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L. -C. Loh, Bob Lowenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Juergen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Dohner, Ayalew Tefferi
Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.
Review
Oncology
Irene Urbino, Carolina Secreto, Matteo Olivi, Vincenzo Apolito, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Semra Aydin, Roberto Freilone, Chiara Dellacasa, Luisa Giaccone, Dario Ferrero, Ernesta Audisio, Alessandro Busca, Marco Cerrano
Summary: The treatment paradigm for older AML patients is becoming increasingly challenging due to the evolving criteria for eligibility, introduction of new agents, implications of precision medicine, and emphasis on quality of life and supportive care. This complex and heterogeneous population is now able to access a wider range of therapeutic options, but managing these options effectively requires careful consideration of each patient's individual characteristics.
Article
Oncology
Anne Tierens, Tracy L. Stockley, Clinton Campbell, Jill Fulcher, Brian Leber, Elizabeth McCready, Peter J. B. Sabatini, Bekim Sadikovic, Andre C. Schuh
Summary: Measurable residual disease (MRD) testing is crucial in adult B-cell acute lymphoblastic leukemia (B-ALL) for prognostic purposes, yet there is a lack of uniform guidelines and consensus in Canada, leading to significant variability in testing approaches. Experts recommend centralized MRD testing and different testing strategies for Ph-negative and Ph-positive patients.
Article
Oncology
Maria H. Gilleece, Avichai Shimoni, Myriam Labopin, Stephen Robinson, Dietrich Beelen, Gerard Socie, Ali Unal, Arnold Ganser, Antonin Vitek, Henrik Sengeloev, Ibrahim Yakoub-Agha, Eleni Tholouli, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Summary: This study evaluated the impact of MRD status at the time of HCT on outcomes for AML CR2 patients. It found that being MRD negative, having good-risk cytogenetics, and longer time from diagnosis to HCT were favorable factors for predicting relapse and leukemia-free survival. In-vivo T cell depletion was predictive of relapse.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Takashi Taga, Shiro Tanaka, Daisuke Hasegawa, Kiminori Terui, Tsutomu Toki, Shotaro Iwamoto, Hidefumi Hiramatsu, Takako Miyamura, Yoshiko Hashii, Hiroshi Moritake, Hideki Nakayama, Hiroyuki Takahashi, Akira Shimada, Tomohiko Taki, Etsuro Ito, Asahito Hama, Masafumi Ito, Katsuyoshi Koh, Daiichiro Hasegawa, Akiko M. Saito, Souichi Adachi, Daisuke Tomizawa
Summary: In patients with ML-DS, detection of MRD after induction therapy, either by FCM or GATA1, was significantly associated with three-year event-free survival and overall survival rates. Positive MRD results were predictive of a higher risk of relapse in ML-DS patients.
Article
Medical Laboratory Technology
Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Bene, Peter Valent, Jeroen te Marvelde, Orianne Wagner-Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink-Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiss, Wolfgang Kern, Arjan van de Loosdrecht
Summary: This article reviews the progress of flow cytometry (FCM) in the diagnosis of myelodysplastic syndrome (MDS) in recent years, and provides optimal methods and recommendations for sample processing, antibody panels and fluorochromes, and current hardware technologies. These recommendations will facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients, but further standardization and harmonization are needed.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Hematology
Priyanka Mehta, Nick Telford, Chris Wragg, Richard Dillon, Sylvie Freeman, Damian Finnegan, Angela Hamblin, Mhairi Copland, Steve Knapper
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Biophysics
Agnieszka Piekarska, Anna Czyz, Christophe Peczynski, Pascale Ambron, Emmanuelle Polge, Ivan Moiseev, Helene Schoemans, Olaf Penack, Zinaida Peric, Grzegorz W. Basak
BONE MARROW TRANSPLANTATION
(2023)
Article
Medicine, Research & Experimental
Piotr Lacina, Rachel E. Crossland, Joanna Wielinska, Anna Czyz, Agnieszka Szeremet, Marek Ussowicz, Tomasz Wrobel, Anne M. Dickinson, Katarzyna Bogunia-Kubik
Summary: This study aimed to identify biomarkers associated with the occurrence of cGvHD by analyzing miRNAs in plasma EVs. The results revealed that hsa-miR-630 and hsa-miR-374b-5p were downregulated in cGvHD patients, while hsa-miR-29c-3p was upregulated.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Corentin Orvain, Eduardo Rodriguez-Arboli, Megan Othus, Brenda M. Sandmaier, H. Joachim Deeg, Frederick R. Appelbaum, Roland B. Walter
Summary: This study retrospectively analyzed 739 patients with de novo AML, 125 with antecedent hematologic disorder (AHD)/AML, and 115 with therapy-related AML who received allografts while in first or second remission. The results showed that relative to patients with de novo AML, relapse rates were similar for patients with AHD and therapy-related AML after multivariable adjustment, as were relapse-free survival and overall survival. Non-relapse mortality was higher for AHD AML. These findings suggest that the clinical history by itself has limited prognostic value for AML patients undergoing allografting.
Editorial Material
Oncology
Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Roland Bruno Walter, Adriano Venditti, Francesco Buccisano
Review
Biochemistry & Molecular Biology
Alessandra Sperotto, Maria Teresa Bochicchio, Giorgia Simonetti, Francesco Buccisano, Jacopo Peccatori, Simona Piemontese, Elisabetta Calistri, Giulia Ciotti, Elisabetta Pierdomenico, Roberta De Marchi, Fabio Ciceri, Michele Gottardi
Summary: Acute myeloid leukemias (AML) consist of multiple subclones that evolve by acquiring additional somatic mutations during the disease progression. The complexity and heterogeneity of AML clone architecture explain the high relapse rate among patients in hematological remission. Monitoring measurable residual disease in AML is challenging due to the difficulty in detecting genetic mutations arising during treatment. Allogeneic hematopoietic stem cell transplant has a prolonged immunological effect that can prevent relapse. Next-generation sequencing can optimize treatment outcome by monitoring measurable residual disease and clonal evolution in AML patients, especially during the transplant phase.
Review
Hematology
Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan
Summary: The European LeukemiaNet has recently updated the clinical and measurable residual disease testing guidelines for acute myeloid leukemia (AML) in 2022 and 2021 respectively. These updates provide new recommendations for classification, risk stratification, prognostication, monitoring, and response assessment in AML patients. Advances in understanding the genetic drivers of AML and its biology have led to the development of novel therapies and more complex clinical treatment guidelines.
Article
Hematology
Roisin Borrill, Kay Poulton, Laura Kusyk, Amy Routledge, Denise Bonney, Ramya Hanasoge-Nataraj, Madeleine Powys, Omima Mustafa, Helen Campbell, Srividhya Senthil, Richard Dillon, Jelena Jovanovic, Suzy Morton, Beki James, Kanchan Rao, Simon Stanworth, Joanne Konkel, Robert Wynn
Summary: Cord blood transplant (CBT) can reduce relapse in high-risk myeloid malignancy, but it remains a major cause of treatment failure. This study observed the safety and tolerability of granulocyte transfusions in CBT recipients, as well as their T-cell expansion, immunophenotype, cytokine profiles, and clinical responses in children with post-transplant relapsed acute leukemia.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Elisa Meddi, Arianna Savi, Federico Moretti, Flavia Mallegni, Raffaele Palmieri, Giovangiacinto Paterno, Elisa Buzzatti, Maria Ilaria Del Principe, Francesco Buccisano, Adriano Venditti, Luca Maurillo
Summary: In acute myeloid leukemia (AML), many patients experience relapse despite achieving complete remission. Traditional morphologic criteria are inadequate for assessing treatment response. Quantification of measurable residual disease (MRD) is a strong prognostic marker in AML, with MRD-negative patients having lower relapse rates and better survival. Different techniques for detecting MRD are available, and their use in guiding post-remission therapy is being actively investigated. Despite controversy, the prognostic value of MRD shows promise in supporting drug development and potentially expediting regulatory approval of new agents.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Iole Cordone, Rachele Amodeo, Silvia Bellesi, Fiorella Bottan, Francesco Buccisano, Maria Stefania De Propris, Serena Masi, Valentina Panichi, Maria Cristina Scerpa, Ombretta Annibali, Velia Bongarzoni, Tommaso Caravita di Toritto, Ugo Coppetelli, Luca Cupelli, Paolo de Fabritiis, Luca Franceschini, Mariagrazia Garzia, Alessia Fiorini, Giacinto Laverde, Andrea Mengarelli, Tommaso Za, Maria Teresa Petrucci
Summary: This study aims to create a uniform and shared report for flow cytometry data in multiple myeloma by involving multiple expert laboratories and clinical hematology units. Through the entire process, including pre-analytical phase, sample processing, data acquisition, analysis, and evaluation, a reliable conclusion is reached based on the most updated principles and recommendations. The necessary data to be included in the clinical report are identified through multiple-choice questionnaires at each stage, with agreement from over 75% of the laboratories considered mandatory.
Article
Oncology
T. Ottone, G. Silvestrini, R. Piazza, S. Travaglini, C. Gurnari, F. Marchesi, A. M. Nardozza, E. Fabiani, E. Attardi, L. Guarnera, M. Divona, P. Ricci, M. A. Irno Consalvo, S. Ienzi, R. Arcese, A. Biagi, L. Fiori, M. Novello, A. Mauriello, A. Venditti, L. Anemona, M. T. Voso
Summary: By analyzing the transcriptome profile of AML patients, researchers found that TWIST1, ECM-receptor interaction, and focal-adhesion pathways were significantly deregulated. The study also showed that metformin can interfere with these processes.
Article
Immunology
Jagoda Siemaszko, Piotr Lacina, Donata Szymczak, Agnieszka Szeremet, Maciej Majcherek, Anna Czyz, Malgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasilowska-Adamska, Patrycja Skowronska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz W. Basak, Sebastian Giebel, Tomasz Wrobel, Katarzyna Bogunia-Kubik
Summary: Transplantation of hematopoietic stem cells can lead to complications such as graft-versus-host disease and CMV infection. This study found that NK cells and their receptors play a role in the transplant outcome. Differences in genetic variants and levels of soluble HLA-E were associated with the development of complications. The study highlights the importance of NK cells in post-transplant complications.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Rory M. Shallis, Naval Daver, Jessica K. Altman, Rami S. Komrokji, Daniel A. Pollyea, Talha Badar, Jan P. Bewersdorf, Vijaya R. Bhatt, Stephane de Botton, Adolfo de la Fuente Burguera, Hetty E. Carraway, Pinkal Desai, Richard Dillon, Nicolas Duployez, Firas El Chaer, Amir T. Fathi, Sylvie D. Freeman, Ivana Gojo, Michael R. Grunwald, Brian A. Jonas, Marina Konopleva, Tara L. Lin, Gabriel N. Mannis, John Mascarenhas, Laura C. Michaelis, Alice S. Mims, Pau Montesinos, Olga Pozdnyakova, Keith W. Pratz, Andre C. Schuh, Mikkael A. Sekeres, Catherine C. Smith, Maximilian Stahl, Marion Subklewe, Geoffrey L. Uy, Maria Teresa Voso, Roland B. Walter, Eunice S. Wang, Joshua F. Fzeidner, Andrius Zucenka, Amer M. Zeidan
Summary: The coexistence of two acute myeloid leukaemia classification systems, proposed by the WHO and the International Consensus Classification in 2022, raises concerns due to consequential disagreements on the diagnosis of acute myeloid leukaemia. This problem threatens the ability of healthcare providers to diagnose and manage the condition, with potential negative impacts on clinical trials, response assessments, and drug development. This viewpoint reviews the merits and limitations of both classification systems and proposes a roadmap for harmonization.
LANCET HAEMATOLOGY
(2023)